Company profile
Sutro Biopharma, Inc.
NASDAQ: STRO · Healthcare · Biotechnology
#348 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
48DFH 42DQ 46GM 64SS 58
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), Piotroski F · ↓ balance-sheet leverage, return on assets
Methodology →Revenue TTM
$99.6M
Rev growth YoY (TTM)
+49.9%
Net income (FY)
-$191.1M
Employees
133
as of 2026-08-13
Market cap
$206.1M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$102.5M$102.5M2025
Net income-$191.1M-$191.1M2025
Operating income-$158.4M-$158.4M2025
Total assets$173.8M$173.8M2025
Liabilities$306.3M$306.3M2025
Equity-$132.5M-$132.5M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Research and Development Services100%
By geography
Not disclosed.
The read
What is Sutro Biopharma, Inc.’s revenue?
Sutro Biopharma, Inc. booked $102.5M in FY2025 revenue, growing 65% year over year — faster than most Healthcare companies we track, at a -186.5% net margin.
Peers · Healthcare
Owlet, Inc.49DPlanet 13 Holdings Inc.44DSanara MedTech Inc.61CViewRay, Inc.——StateHouse Holdings Inc.——Beta Bionics, Inc.58CNeighbors
San Mateo →Key facts
CEOJane Chung
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: STRO
Employees133
IPO date2018-09-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.